On the Reactivity of Pyridoxal-5'-phosphate with Yeast tRNA^{Phe} and tRNA^{Tyr}

Nobuo Okabe* and Friedrich Cramer

Max-Planck-Institut für experimentelle Medizin, Abteilung Chemie, Hermann-Rein-Straße 3, D-3400 Göttingen

Z. Naturforsch. **35 c**, 522–525 (1980); received February 11/March 17, 1980

Yeast tRNA Phe, Yeast tRNA Tyr, Pyridoxal-5'-phosphate

Yeast tRNA^{Phe} and tRNA^{Tyr} were reacted with the fluorescent reagent pyridoxal-5'-phosphate and the modified tRNAs were analysed with respect to the number and position of modified nucleosides and with respect to aminoacylation.

a) Following the intrinsic fluorescence of pyridoxal-5'-phosphate, the treatment of tRNA^{Tyr} with increasing amounts of pyridoxal-5'-phosphate revealed about 50 mol of reagent or a even higher number bound per one mol of tRNA^{Tyr}. After borohydride reduction (in order to stabilize the linkage) of this modified tRNA^{Tyr} and purification with reverse phase chromatography a modified tRNA^{Tyr} was obtained carrying about 2 mol of the reagent.

b) Both tRNA^{Tyr} and tRNA^{Phe} treated with pyridoxal-5'-phosphate and reduced exhibited almost unchanged aminoacylation as compared to the unmodified tRNAs.

c) Pyridoxal-5'-phosphate treated and reduced tRNA^{Phe} and tRNA^{Tyr} were digested with ribonuclease T₁ and the resulting oligonucleotides were separated. However, no fluorescent oligonucleotide and no difference to an oligonucleotide pattern obtained from unmodified tRNA were observed.

Thus, pyridoxal-5'-phosphate might have been bound to the highly purified yeast tRNA^{Phe} and tRNA^{Tyr} samples either via an unstable linkage or not covalently. This result is controversial with respect to the specific reaction of pyridoxal-5'-phosphate with unfractionated tRNAs from colon carcinoma and tRNAs from *E. coli* as reported in the literature.

Introduction

The aim of modification of tRNA by a fluorescent reagent is to obtain information on tRNA structure as well as on tRNA-protein interaction. The fluorescent dye has to bind specifically to one or a few nucleosides in the tRNA [for reviews see 1-4] and the reaction conditions have to be mild so that neither damage to the structure of tRNA nor incorrect recognition resulting in misaminoacylation occurs

* Permanent address: Osaka University, Faculty of Pharmaceutical Sciences, Osaka 565, Japan.

Reprint requests to Dr. F. Cramer.

0341-0382/80/0500-0522 \$ 01.00/0

Recently Kopelovich and Wolfe [5] modified unfractionated tRNA from human colon carcinoma and some *Escherichia coli* tRNAs with pyridoxal-5′-phosphate. They suggested that the aldehyde group of the reagent might react with an amino group of the tRNA and the resulting Schiff base might be transformed in a stable covalent C-N linkage by borohydride reduction. In particular guanosine 20 in the dihydrouridine loop of the tRNA seemed to be reactive from inhibition studies with N-acetoxy-2-acetylaminofluorene [6] using unfractionated *E. coli* tRNA. This course of reaction was also suggested from the reaction of the related aldehydes kethoxal and glyoxal with tRNA Phe as reported in the literature [7].

Since pyridoxal-5'-phosphate should react mildly [5], is fluorescent [8], and is not very large, we aimed to prepare yeast tRNA Phe and tRNA Tyr modified in the dihydrouridine loop with this reporter group.

$$H_2O_3POCH_2$$
 OH
 CH_3
 $-CH=N$
 $-CH_2-NH$

Experimental

Materials

Pyridoxal-5'-phosphate was purchased from Boehringer (Mannheim), sodium borohydride, salts and buffer substances (ultrapure grade) from Merck (Darmstadt), RNase T₁, E.C. 3.1.4.8, from Sankyo (Tokyo, Japan), snake venom phosphodiesterase (1 mg/ml), E.C. 3.1.4.18, and alkaline phosphatase from *E. coli* (1 mg/ml), E.C. 3.1.3.1, from Boehringer (Mannheim), and [14C]phenylalanine and [14C]tyrosine (50 Ci/mol) from Schwarz Bioresearch (Orangeburg, USA). tRNA Phe and phenylalanyltRNA synthetase, E.C. 6.1.1.20, from yeast were isolated according to [9, 10], tRNA Tyr and tyrosyltRNA synthetase, E.C. 6.1.1.1, from yeast according to [11].

Spectroscopy

Ultraviolet absorbance measurements were performed with a Shimazu double beam spectropho-



tometer UV-200 and a Zeiss PMQ-3 spectrophotometer. Relative fluorescence intensities were measured with a modified Farrand MK-1 spectrofluorometer equipped with a Varian-F-80 A X-Y-recorder.

Fluorescence titration

 $100\,\mu l$ samples containing $1\,A_{260}$ unit of tRNA and various amounts of reagent were incubated at 37 °C for 30 min in 20 mM borate buffer, pH 8.0, containing 5 mM MgSO₄. The reaction mixture was passed through a Sephadex G-25 column (1.7 × 38 cm) equilibrated with water at pH 6.0. The fluorescence intensity of the eluate was measured by using 37 μM pyridoxal-5′-phosphate in aqueous solution at pH 6.0 as a standard at 20 °C. The observed fluorescence intensity was then calculated as relative fluorescence intensity per A_{260} unit of tRNA.

Reaction of pyridoxal-5'-phosphate with tRNA

30-300 nmol tRNA (20-200 A₂₆₀ units) were reacted with pyridoxal-5'-phosphate dissolved in water of pH 8.0, in 20 mm borate buffer, pH 8.0, containing 5 mm MgSO₄ in a total volume of 1-2 ml. The reaction was continued at 37 °C for 30-60 min. Then the mixture was cooled in the ice bath and tRNA was precipitated by adding three volumes of cold ethanol in 0.2 M KCl. After centrifugation, the precipitant was washed with cold ethanol followed by vacuum drying. Then it was dissolved in 1 ml of 0.2 M Tris-HCl, pH 7.5, containing 5 mm MgCl₂ and reduced by adding a 3500-7000 fold molar excess of NaBH₄ dissolved in 500 µl of cold 0.2 M Tris-HCl, pH 7.5, containing 5 mm MgCl₂. Reduction was continued for 15-30 min at 0 °C in the dark, and then free NaBH4 was hydrolyzed by addition of 1 N acetic acid to pH 4 in the ice bath. tRNA was separated from the reagents on a Sephadex G-25 column $(1.7 \times 38 \text{ cm})$ equilibrated with water. The pooled tRNA fractions were concentrated and loaded on a RPC-5 column $(0.7 \times 90 \text{ cm})$ equilibrated with 50 mMphosphate buffer pH 7.0, containing 10 mm MgSO₄ and 0.4 M NaCl. After washing with the same buffer, the tRNA was eluted with a linear gradient of 2×250 ml, 0.4 m to 1.0 m NaCl in 50 mm phosphate buffer, pH 7.0, containing 10 mm MgSO₄ at 40 °C. The appropriate fractions were pooled and dialyzed against water in the cold room, then these samples were concentrated and reprecipitated with ethanol in 0.2 M KCl to remove any contamination. The precipitant was dissolved in a small volume of water and desalted on a Biogel P-2 column $(1.5 \times 30 \text{ cm})$ equilibrated with water. The pyridoxal-5'-phosphate treated tRNAs were stocked at -20 °C.

Aminoacylation

100 μl of the reaction mixture contained 150 mm Tris-HCl, pH 7.5, 50 mm KCl, 5 mm ATP, 0.05 mm [¹⁴C]phenylalanine or [¹⁴C]tyrosine and about 0.2 A₂₆₀ units of tRNA. It was started by adding 3.4 μg of phenylalanyl-tRNA synthetase or 10.5 μg of tyrosyl-tRNA synthetase. In 10 μl aliquots the acid-precipitable radioactivity was determined [9–11].

Ribonuclease T_1 cleavage of modified tRNA and oligonucleotide separation


 $3~A_{260}$ units of tRNA^{Phe} treated with NaBH₄ and $15~A_{260}$ units of tRNA^{Phe} treated with pyridoxal-5'-phosphate and NaBH₄ as described above were incubated with 100 and 250 units of RNase T₁ in 1.5 ml of 50 mm Tris-HCl, pH 7.5 at 37 °C for 16 h, respectively. The reaction mixture was adjusted to 20 mm Tris-HCl, pH 7.5 and 7 m urea and then loaded on a DEAE-cellulose column (0.7 × 85 cm) equilibrated with 20 mm Tris-HCl, pH 7.5. The column was eluted with a linear gradient of 2 × 200 ml 0 m to 0.3 m NaCl in 20 mm Tris-HCl, pH 7.5 at a flow rate of 16 ml/h.

 $34\,A_{260}$ units of tRNA^{Tyr} treated with pyridoxal-5'-phosphate and NaBH₄ were digested with 500 units of RNase T₁ and further dealt with as above.

Results

Reaction of $tRNA^{Tyr}$ and $tRNA^{Phe}$ with pyridoxal-5'-phosphate

tRNA^{Tyr} was reacted with a 10-500 fold excess of pyridoxal-5'-phosphate in an aqueous borate buffer in the presence of Mg²⁺ at pH 8 and the excess of reagent was removed by gel filtration. This pyridoxal-5'-phosphate treated tRNA^{Tyr} exhibited fluorescence excitation and emission maxima of 330 nm and 420 nm (Fig. 1), which correspond to the respective maxima of free pyridoxal-5'-phosphate in aqueous solution. The measured fluorescence was normalized to a standard solution of the reagent. The number of pyridoxal-5'-phosphate molecules bound to tRNA^{Tyr} was estimated assuming that its



MOLECULES PYRIDOXAL-51-PHOSPHATE PER MOLECULE tRNATyr

Fig. 1. Relative fluorescence intensity of pyridoxal-5'-phosphate treated tRNA^{Tyr} at various initial molar ratios of reagent to tRNA^{Tyr}. Excitation was done at 330 nm, emission was measured at 420 nm. Insert: uncorrected fluorescence excitation and emission spectra of pyridoxal-5'-phosphate treated tRNA^{Tyr} (in 10⁻⁴ M aqueous solution at pH 3.8 and 20 °C). Band widths of 5 and 10 nm at the excitation and emission side, respectively, were used.

fluorescence quantum yield is unchanged upon binding to tRNA as is the quantum yield of pyridox-amine-5'-phosphate upon complex formation with human or bovine serum albumin [8]. As is evident from Fig. 1 saturation of tRNA^{Tyr} was observed at a molar ratio of pyridoxal-5'-phosphate over tRNA^{Tyr} in the range of 50–200.

In contrast the number of pyridoxal-5'-phosphate molecules bound to tRNA^{Tyr} considerably changed when borohydride reduction [12] was performed after the pyridoxal-5'-phosphate treatment and the tRNA^{Tyr} was then purified by RPC-5 chromatography. It eluted in a major fraction corresponding to 95% of the applied tRNA^{Tyr}. The mean number of pyridoxal-5'-phosphate molecules bound to tRNA^{Tyr} in this fraction is 2.3, irrespective of the initial molar ratio of the reagent to tRNA^{Tyr}. No absorbance change was observed at all with this modified yeast tRNA^{Tyr} around 325 nm, whereas

Kopelovich and Wolfe [5] with human and *E. coli* tRNAs reported appearance of an absorption peak at that wavelength.

With yeast tRNA^{Phe} the estimation of the number of pyridoxal-5'-phosphate molecules bound per molecule of tRNA^{Phe} by means of fluorescence was not possible, because of the overlapping emission spectra of pyridoxal-5'-phosphate and the Y base of tRNA^{Phe}. Nevertheless tRNA^{Phe} was treated in the same way as tRNA^{Tyr} and identified by oligonucleotide analysis.

Aminoacylation of pyridoxal-5'-phosphate treated tRNA^{Phe} and tRNA^{Tyr}

The aminoacylation was investigated under standard aminoacylation conditions [9–11] and determined to be 1600 pmol tyrosine per A₂₆₀ unit to tRNA^{Tyr} and 1750 pmol phenylalanine per A₂₆₀ unit of tRNA^{Phe}. Aminoacylation of the modified tRNAs as described above led to a small enhancement of 2% with tRNA^{Tyr}, whereas a reduction of 8% in aminoacylation was observed with tRNA^{Phe}. Thus the modification of tRNA^{Phe} and tRNA^{Tyr} with pyridoxal-5′-phosphate has only minor influence on the extent of aminoacylation compared to the native tRNAs.

Separation of oligonucleotides from ribonuclease T_1 digestion of pyridoxal-5'-phosphate treated $tRNA^{Phe}$ and $tRNA^{Tyr}$

Native $tRNA^{Phe}$ was treated with sodium borohydride, digested with RNase T_1 , and the resulting oligonucleotides were separated on DEAE cellulose (Fig. 2a). Concomitantly $tRNA^{Phe}$ which was first




Fig. 2. Separation of oligonucleotides obtained by digestion with ribonuclease T_1 of a) $tRNA^{Phe}$ treated with sodium borohydride, b) $tRNA^{Phe}$ treated with pyridoxal-5'-phosphate followed by borohydroxide reduction and c) $tRNA^{Tyr}$ treated with pyridoxal-5'-phosphate followed by borohydride reduction. Relative fluorescence at 420 nm (····), UV absorbance at 254 nm (---).

reacted with excess pyridoxal-5'-phosphate, subsequently reduced by sodium borohydride, was then digested with RNase T₁ and the resulting oligonucleotides were separated analogously (Fig. 2b). The composition of oligonucleotides and their respective elution volumes are nearly identical in both tRNA^{Phe} samples. However, no fluorescent oligonucleotide, resulting from modification with pyridoxal-5'-phosphate, was detected. Only one fluorescent oligonucleotide was observed in both elution patterns and was identified by nucleoside analysis as being the Y base containing dodecanucleotide.

tRNATyr was treated analogously as tRNAPhe, reduced with borohydride and digested in one case (data not shown), and reacted with pyridoxal-5'phosphate prior to reduction and digested in the other case (Fig. 2c). Again, no fluorescent oligonucleotide, revealing the fluorescence characteristics of pyridoxal-5'-phosphate, could be detected.

1] S. H. Kim, Adv. Enzymol. **46**, 279–315 (1978).

- [2] J. P. Goddard, Progr. Biophys. Mol. Biol. 32, 233-308 (1977).
- [3] H. G. Faulhammer, M. Sprinzl, and F. Cramer, Molecular Mechanisms of Biological Recognition (M.
- Balaban, ed.), p. 205–225, Elsevier/North Holland, Amsterdam/New York 1979.

 [4] C. R. Cantor and T. Tao, Procedures in Nucleic Acid Research (G. L. Cantoni and D. R. Davies, eds.), Vol. 2, p. 31–93, Harper and Row, New York
- [5] L. Kopelovich and G. Wolfe, Biochemistry 16, 3721 -3726 (1977).
- [6] P. Pulkrabek, D. Grunberger, and I. B. Weinstein, Biochemistry 13, 2414 – 2419 (1974).

Concluding Remarks

In the present investigation evidence is presented, that pyridoxal-5'-phosphate is not reacting with yeast tRNA^{Phe} and tRNA^{Tyr} with formation of a stable covalent linkage. Since linking via reduced Schiff base seems to be stable upon RNase T, digestion as reported in the case of proflavine and ethidium bromide linkage to tRNAPhe [12], we have to conclude that with yeast tRNA Phe and tRNA Tyr pyridoxal-5'-phosphate may have not so a specific reactivity towards guanosines as has been reported previously [5] for unfractionated human colon carcinoma tRNA and some E. coli tRNAs.

Acknowledgements

Dr. N. Okabe thanks the Alexander von Humboldt-Stiftung for supporting his stay in Germany and Dr. D. Gauss for discussions during the preparation of this manuscript.

M. Litt, Biochemistry 10, 2223-2227 (1971).

- [8] J. E. Churchich and L. Harpring, Biochim. Biophys. Acta **105**, 575 – 582 (1965); J. E. Churchich, Biochim. Biophys. Acta **102**, 280 – 288 (1965).
- D. Schneider, R. Solfert, and F. von der Haar, Hoppe-Sevler's Z. Physiol. Chem. 353, 1330-1336 (1972).
- 10] F. von der Haar, Eur. J. Biochem. 34, 84-90 (1973).
- [11] H. G. Faulhammer and F. Cramer, Eur. J. Biochem. **75,** 561 – 570 (1977).
- [12] W. Wintermeyer and H. G. Zachau, Methods Enzymol. **29**, 667–673 (1974); W. Wintermeyer and H. G. Zachau, FEBS Letters **18**, 214–218 (1971).